Forward – Looking Statements This Presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact included in this Presentation, regarding our strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects, guidance, plans and objectives of management are forward- looking statemen ...

公司核心事件 - Eikon Therapeutics将于2026年8月20日上午9:00（美国东部时间）举办一场关键意见领袖（KOL）活动，由Cantor Fitzgerald主办 [1] - 公司董事长兼首席执行官Roger M Perlmutter博士将参与该活动 [1] - 活动将邀请德克萨斯大学MD Anderson癌症中心的医学肿瘤学家兼医师科学家Timothy A Yap博士作为主讲嘉宾 [1] - 活动将由Cantor Fitzgerald的Imogen Mansfield主持 [3] - 活动网络直播存档可在公司投资者关系网站查阅，重播将在活动后保留30天 [3] 公司业务概况 - Eikon是一家晚期临床阶段的生物制药公司，致力于开发创新药物以解决严重未满足的医疗需求 [1][4] - 公司初始专注于肿瘤学领域，推进针对高未满足需求领域的候选药物管线 [4] - 公司部署专有技术平台，包括其专有的单分子追踪系统，用于开发内部衍生的新型疗法 [4] - 公司利用管理团队的深厚专业知识进行许可引进有前景的资产 [4] - 公司愿景是通过有目的地整合传统生物学研究与先进工程，更快地开发更好的药物，成为一代领导者 [4] 行业专家观点 - Timothy A Yap博士现任MD Anderson癌症中心治疗发现部门临床开发副总裁兼负责人 [2] - Yap博士是实验癌症治疗（I期项目）和胸部/头颈内科肿瘤学系的教授 [2] - Yap博士是多项评估靶向DNA损伤反应新策略的临床试验和转化研究的首席研究员 [2] - Yap博士是肿瘤学中PARP抑制剂使用的专家 [2] - Yap博士将讨论PARP抑制在乳腺癌、卵巢癌、前列腺癌和胰腺癌中的当前治疗格局 [2] - 讨论内容包括已获批药物的使用、治疗结果以及当前靶向PARP和PARylation药物的局限性 [2] - Yap博士接受Eikon的顾问报酬，该财务关系已向MD Anderson利益冲突委员会披露 [2]

HONG KONG, Aug. 18, 2026 (GLOBE NEWSWIRE) -- ZW Data Action Technologies Inc. (the “Company”) (Nasdaq:CNET), an integrated online advertising, precision marketing, data analytics and other value-added services provider serving enterprise clients, today announced that it received a formal notification from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”), dated August 17, 2026, indicating that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires li ...

公司融资活动 - Singularity Future Technology Ltd与一家机构投资者签订证券购买协议，以每股3美元的价格发行60万股普通股（或预付费权证替代）[1] - 此次注册直接发行的总收益预计约为180万美元，扣除配售代理费和其他发行费用前[2] - 发行预计于2026年8月19日左右完成，Univest Securities, LLC担任独家配售代理[2] - 该发行依据公司此前向SEC提交并于2024年10月24日生效的S-3表格上架注册声明（文件编号333-282006）进行[3] 公司业务概况 - 公司是一家全球物流综合解决方案提供商，2001年在美国成立[5] - 公司主要专注于提供货运物流服务，包括为钢铁公司和电子商务企业提供航运、仓储、资源、设备及其他物流支持[5]

核心观点 - Jefferson Capital通过其间接全资子公司发行1亿美元8.250%优先票据，用于偿还循环信贷额度借款及一般公司用途 [1][2] 发行条款 - 发行总额为1亿美元（$100 million）的8.250%优先票据，到期日为2030年 [1] - 该票据为现有5亿美元（$500 million）8.250%优先票据的增发，两者合并构成同一系列票据 [1] - 票据由发行人部分全资境内受限子公司提供高级无担保全额无条件担保 [1] - 发行依据为2025年5月2日签署的契约文件 [1] - 发行预计于2026年8月20日完成，受惯例交割条件约束 [2] 资金用途 - 净收益将用于偿还循环信贷额度下的部分未偿还借款 [2] - 剩余资金用于一般公司用途 [2] - 发行人未来可能重新借入循环信贷额度资金，用于购买资产组合及资助收购 [2] 发行方式 - 票据未根据《证券法》或任何州证券法注册 [3] - 仅向合格机构买家（Rule 144A）及美国境外非美国人士（Regulation S）发售 [3]

PresentationGreetings, and welcome to the Ensysce Biosciences, Inc. Corporate Update Call. [Operator Instructions] It is now my pleasure to introduce your host, Dr. Lynn Kirkpatrick, Chief Executive Officer. Thank you. You may begin.D. KirkpatrickPresident, CEO & Director Thank you, operator, and good morning, everyone. Thank you for joining us. We recently issued a press release outlining our acquisition of Cy Biopharma and a concurrent private placement financing. That release, along with an updated corpo ...

Vancouver, British Columbia--(Newsfile Corp. - August 18, 2026) - Dryden Gold Corp. (TSXV: DRY) (OTCQX: DRYGF) (FSE: X7W) ("Dryden Gold" or the "Company") announces that, further to its news releases dated July 6, 2026 and August 12, 2026, the TSX Venture Exchange ("TSXV") has approved for filing the Company's option agreement with Orebot Inc. ("Orebot"), an arm's length party, dated June 29, 2026 (the "Agreement"), to acquire a 100% interest in the Lost Lake Property (the "Property"), comprised of 122 ten ...

Vancouver, British Columbia--(Newsfile Corp. - August 18, 2026) - Phenom Resources Corp. (TSXV: PHNM) (OTCQX: PHNMF) (FSE: 1PY0) ("Phenom" or the "Company") announces that it has completed the final payments and work expenditures required to exercise the option (the "Option") to acquire a 100% interest in the Dobbin property (the "DobbinProject"). The Dobbin Project located in central Nevada lies on the southern extension of the Independent-Eureka gold trend and displays all of the ingrediencies of a regio ...

公司上市进展 - Devonian Health Group Inc预计其普通股和认股权证将在NYSE American上市，交易最早于2026年8月21日开始，股票代码分别为“DHGR”和“DHGR WS”，但需视市场条件和NYSE American的最终批准而定[1] - 公司将继续在TSX Venture Exchange上市，并已预留TSXV上的“DHGR”代码，计划稍后将当前交易代码从“GSD”更改为“DHGR”[1] - 此次上市与一项包销公开发行相关[1] 公司业务概况 - Devonian是一家临床阶段的制药公司，专注于开发针对多种自身免疫性纤维炎症性疾病的新疗法，以满足未满足的医疗需求[2] - 公司核心策略是开发治疗纤维炎症性自身免疫疾病的处方药，包括但不限于特应性皮炎、放射性皮炎和溃疡性结肠炎[2] - 公司成立于2015年，总部位于加拿大魁北克，拥有最先进的提取设施[3] - 公司目前在TSXV上市（代码：GSD），并在OTCQB Venture Market报价（代码：DVHGF）[3]

Multi-year agreement with Peak Medical expands UroShield commercialization across the United Kingdom and Republic of IrelandTYLER, Texas, Aug. 18, 2026 (GLOBE NEWSWIRE) -- ENvue Medical (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company, today announced a new exclusive distribution agreement with Peak Medical, a complete medical equipment solutions company, to expand commercial distribution of ENvue’s UroShield® device across the United Kingdom and Republic of Ireland. The ...